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hNTRODUCTION
Recent conceptual and technologic advances in
he areas of molecular immunobiology, gene trans-
er, and cell processing have fostered increasingly
ophisticated translational applications of cellular
herapies for oncologic disease that use genetically
odiﬁed T lymphocytes. This minireview will
ighlight these advances and their relevance to the
evelopment of strategies to target post–autologous
ransplantation minimal residual disease with adop-
ively transferred T cells engineered to have graft-
ersus-tumor (GVT) reactivity. A central feature of
hese strategies is the genetic modiﬁcation of T cells
o express antigen receptors for re-directed tumor
peciﬁcity, because in the autologous setting, GVT
ffects from donor T-cell recognition of recipient
inor histocompatibility antigens (mHAs) are not
perative. In the context of adoptive transfer with
espect to the conditioning of the recipient for
nhanced T-cell engraftment and expansion, the
rafting of chimeric antigen receptors (CARs)
n to T cells with endogenous T-cell receptor
TCR) speciﬁcities for viral epitopes to which the
ost has robust immunity will also be discussed.
he backlog in clinical deployment of these tech-
ologies is now being rectiﬁed by the implementa-
ion of an increasing number of early-phase cellular
mmunotherapy clinical trials and institutions sup-
orting them. G
4ARADIGM OF IMMUNOLOGIC CLEARANCE OF
ALIGNANCY: THE GVT EFFECT AFTER ALLOGENEIC
EMATOPOIETIC STEM CELL/T-CELL
RANSPLANTATION
Increasing understanding of the molecular under-
innings of immune system regulation has provided
ovel opportunities for therapeutic immune system
anipulation, including tumor immunotherapy. To
ate, cellular immunotherapy of cancer has been most
uccessful in the area of allogeneic hematopoietic stem
ell (HSC)/T-cell transplantation for hematologic
eoplasias. Evidence supporting cellular immune-me-
iated eradication of residual tumor cells after donor
-cell engraftment can be inferred by comparing the
isparate relapse rates between recipients of syngeneic
nd non–T-cell depleted matched sibling transplants
1,2]. Patients with chronic myelogenous leukemia in
hronic phase, acute myelogenous leukemia in ﬁrst
omplete remission, and acute lymphoblastic leukemia
n ﬁrst complete remission who underwent stem cell
ransplantation from a syngeneic donor had an actu-
rial probability of relapse at 3 years of 45%, 49%, and
1%, respectively, whereas the rates for recipients of
cell–replete transplants from an HLA-identical sib-
ing for the same diseases were 12%, 20%, and 24%,
espectively [3,4]. GVT responses after allogeneic
SC/T-cell transplantation are not limited solely to
ematologic neoplasias. In an exciting extension of
VT activity, Childs et al. [5] and Drachenberg and
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Posttransplantation Adoptive Transfer of T Cells
Bhilds [6] observed regressions of metastatic renal cell
arcinoma after nonmyeloablative HSC/T-cell al-
ografting. The extent to which GVT responses can
e exploited to effect the regression of other solid
umors requires further exploration [7].
CELLS AS EFFECTORS OF THE GVT EFFECT
Studies in animal models have established that
onor major histocompatibility complex–restricted
D8 and CD4  T-cell antigen receptor (TCR)
-cells speciﬁc for mHAs encoded by polymorphic
enes that differ between the donor and recipient are
he principal mediators of acute graft-versus-host dis-
ase and the GVT effect [8-10]. Patients with chronic
yelogenous leukemia in chronic phase who relapse
fter allogeneic bone marrow transplantation have
een identiﬁed as a patient population for whom do-
or lymphocyte infusion successfully promotes tumor
ell eradication [11]. Complete response rates of ap-
roximately 75% are achieved with donor lymphocyte
nfusion cell doses in the range of 0.25 to 12.3  108
ononuclear cells per kilogram [11,12]. A growing
umber of polymorphic genes encoding mHAs with
estricted hematopoietic expression that elicit donor
ntigen-speciﬁc T-cell responses have been identiﬁed
13,14]. The isolation, ex vivo expansion, and reinfu-
ion of donor-derived clones speciﬁc for these cell
ineage–speciﬁc mHAs has the exciting potential of se-
ectively augmenting GVT for hematologic malignan-
ies without exacerbating graft-versus-host disease [15].
EYOND GVT: CELLULAR IMMUNOTHERAPY USING
X VIVO–EXPANDED T CELLS WITH DEFINED
NTIGEN SPECIFICITY
The strategy of isolating and expanding antigen-
peciﬁc T cells as a therapeutic intervention for hu-
an disease has now been validated in a variety of
linical trials [16,17]. Initial studies conducted by
iddell and Greenberg have established the utility of
doptive T-cell therapy with CD8 cytotoxic T lym-
hocyte clones speciﬁc for cytomegalovirus (CMV)–
ncoded antigens as a means of reconstituting deﬁ-
ient viral immunity in the setting of allogeneic bone
arrow transplantation and have deﬁned the princi-
les and methods for T-cell isolation, cloning, expan-
ion, and reinfusion [18]. A similar approach has been
ioneered by Heslop and Rooney for controlling post-
ransplantation Epstein-Barr virus (EBV)–associated
ymphoproliferative disease. EBV-speciﬁc donor-de-
ived T cells have the capacity to protect patients at
igh risk for this complication after T cell–depleted
SC allografting and to mediate the regression of
ymphoproliferative disease, which clinically mimics
mmunoblastic B-cell lymphoma [19,20]. Moreover, t
B&MTegressions of EBV nasopharyngeal carcinoma have
een observed in clinical trials by this group in re-
ponse to the transfer of autologous ex vivo–expanded
BV-speciﬁc T-cell lines, whereas studies targeting
odgkin lymphoma are in progress with EBV latent
embrane protein–2–speciﬁc T-cells [20-22]. In ag-
regate, these studies clearly demonstrate that adoptively
ransferred ex vivo–expanded T cells can mediate anti-
en-speciﬁc effector functions with limited toxicities and
ave been facilitated by targeting deﬁned virally encoded
ntigens to which T-cell donors have established immu-
ity.
ANCER IMMUNOTHERAPY USING ADOPTIVELY
RANSFERRED AUTOLOGOUS ANTIGEN-SPECIFIC
CELLS
Until recently, the translation of insights made
rom the animal adoptive therapy model systems to
he treatment of human malignancy has been limited
y the paucity of molecularly deﬁned human tumor
ntigens capable of eliciting an autologous T-cell re-
ponse and the difﬁculty of isolating functional T cells
ith high-afﬁnity antigen receptors from cancer pa-
ients. Consequently, initial cellular immunotherapy
rials using autologous antitumor effector cells relied
n antigen-nonspeciﬁc effectors such as lymphokine-
ctivated killer cells. This had limited efﬁcacy and
ften pronounced toxicities [23-26]. In an attempt to
nhance the tumor speciﬁcity and potency of infused
ffector cells, interleukin (IL)–2–expanded tumor-in-
ltrating lymphocytes (TILs) or T cells harvested
rom vaccination site draining lymph nodes were eval-
ated, particularly in the melanoma patient popula-
ion [27,28]. Responses to TIL infusions were spo-
adic, in part because of the heterogeneous population
f cells expanded with unpredictable antitumor spec-
ﬁcities. Patients with melanoma, however, can expe-
ience striking tumor regressions after TIL infusions
f oligoclonal populations of T cells speciﬁc for de-
ned melanocyte cell lineage antigens.
Expression cloning technologies are identifying a
rowing array of genes encoding human tumor anti-
ens that elicit T-cell responses, thereby facilitating in
itro culture systems for generating tumor-speciﬁc T
ells from cancer patients [29,30]. The identiﬁcation
nd validation of tumor-expressed polypeptides that
re proteolytically processed, loaded on to HLA class
molecules, and transported to the cell surface, where
hey are subject to surveillance by class I–restricted T
ells bearing clonotypically unique T-cell antigen re-
eptors, have revealed several important classes of
umor antigens. These include tumor-speciﬁc anti-
ens arising from (1) mutated genes in the cancer cells
hemselves or from altered reading frames used by
umor cell transcriptional/translational machinery, (2)
35
a
r
p
c
a
g
C
C
T
o
a
t
c
a
t
c
M
e
a
c
R
E
e
a
i
a
O
o
m
s
i
t
H
H
w
e
s
t
t
m
T
b
c
f
M
v
b
C
r
i
d
t
o
p
u
r
s
b
c
m
c
F
b
n
t
a
s
t
i
b
i
u
p
c
h
H
e
t
c
a
b
a
e
C
a
l
p
o
W
C
o
i
C
p
c
n
p
C
s
M. Jensen
3berrantly expressed nonmutated genes that have a
estricted pattern of expression limited to immuno-
rivileged anatomic locations such as the testis, and (3)
ell lineage–speciﬁc genes [31]. Technologies are also
dvancing for identifying similar types of tumor anti-
ens that elicit HLA class II–restricted T cells [31].
HALLENGES TO APPLICABILITY AND EFFICACY OF
ANCER CELLULAR IMMUNOTHERAPY
Whereas progress in the ﬁeld of tumor adoptive
-cell therapy has made important proof-of-principle
bservations, the feasibility of a more broad-based
pplication of this therapeutic strategy is limited by
echnologic feasibility constraints pertaining to the
umbersome and labor-intensive culture systems that
re currently in use to isolate T-cell populations, par-
icularly from heavily treated cancer patients who be-
ome candidates for autologous HSC transplantation.
oreover, clinical experience to date has revealed that
x vivo numeric expansion of tumor-reactive T cells
nd subsequent adoptive transfer is not always sufﬁ-
ient for actualizing therapeutic efﬁcacy.
E-DIRECTED T-CELL TUMOR SPECIFICITY BY
XPRESSING  TCR HETERODIMERS
The genetic grafting of high-afﬁnity  TcR het-
rodimers speciﬁc for therapeutically useful tumor
ntigens is a conceptually attractive approach to rap-
dly generate de novo effector cells for adoptive ther-
py from T cells lacking tumor antigen speciﬁcity.
ne application of this strategy would be the cloning
f TCR chains with speciﬁcities for GVL mHA poly-
orphic genes that are cell-lineage speciﬁc (for in-
tance, B-cell speciﬁc). The grafting of these TCRs
nto autologous T cells would transfer GVL reactivity
o an autologous effector cell for use after autologous
SC transplantation. This strategy requires that the
LA restriction of the transferred TcR be matched
ith the HLA type of the recipient. From a transgene
xpression perspective, this approach also requires
ufﬁcient and fairly balanced expression of 2 polypep-
ides. The initial demonstrations of T-cell speciﬁcity
ransfer through transfer of TcR heterodimers in pri-
ary human T lymphocytes involved the transfer of
cR chains speciﬁc for melanoma antigen recognized
y T cells (MART)-1 [32] and human immunodeﬁ-
iency virus [33]. Since then, transfer of TcR speciﬁc
or additional antigens, including MDM2 [34] and
AGE-A1 [35], has been described, and recent re-
iews describing the potential of TcR transfer have
een published [36,37]. m
6ARS DERIVED FROM SINGLE-CHAIN ANTIBODY Fv
Studies evaluating the biology of T-cell antigen
eceptor signal transduction revealed that cross-link-
ng chimeric molecules consisting of the extracellular
omain of CD8, fused to the intracellular domain of
he CD3-, resulted in activation of T-cell hybrid-
mas mimicking that of the endogenous TCR com-
lex [38-40]. Concurrently, engineered immunoglob-
lin molecules consisting of single-chain variable
egions joined by ﬂexible amino acid linkers were
hown to assume conformations capable of antigen
inding [41]. CARs evolved from the fusing of extra-
ellular single-chain antibodies to the intracellular do-
ain of the CD3- or FcRIII chain [42]. These
ell-surface chimeric molecules (single-chain antibody
v [scFv]Fc:) are distinguished by their ability to both
ind antigen and transduce activation signals via immu-
oreceptor tyrosine-based activation motifs present in
heir cytoplasmic tails.
The genetic modiﬁcation of T cells to synthesize
n scFvFc: for re-directed antigen speciﬁcity is one
trategy to generate effector cells for adoptive therapy
hat does not rely on preexisting antitumor T-cell
mmunity. These receptors are “universal” in that they
ind antigen in a major histocompatibility complex–
ndependent fashion; thus, 1 receptor construct can be
sed to treat a population of patients with antigen-
ositive tumors. A notable additional advantage asso-
iated with antibody-based chimeras compared with
eterodimeric TCRs is the potential of targeting
LA-deﬁcient tumor cells, as well as nonpolypeptide
pitopes such as lipids and carbohydrates. Moreover,
he same chimera can be used to redirect both CD8
ytotoxic T lymphocyte cytolytic effector functioning
nd CD4 helper functioning [43]. Increasingly ro-
ust animal models have demonstrated the capacity of
doptively transferred scFvFc:-expressing T cells to
radicate established tumors in vivo [44-46].
Our group has focused on designing scFvFc:
ARs speciﬁc for the B-cell lineage markers CD20
nd CD19 for targeting B-cell lineage lymphomas and
eukemias [47,48]. Although these receptors are ex-
ressed on nonneoplastic B cells, they are not expressed
n HSCs or immunoglobulin-secreting plasma cells.
e anticipate that adoptive therapy using CD20- and
D19-speciﬁc CAR–re-directed T cells might have
ptimal utility in eradicating posttransplantation min-
mal residual disease or disease refractory to anti-
D20 antibody targeting because of host Fc receptor
olymorphisms and an anatomic location of tumor
ells that is selectively accessible by T cells. Recog-
izing that B cells produced by marrow stem cell
recursors are a continuous source of antigen for these
AR–re-directed T cells in vivo, control of the per-
istence of these T cells is potentially important and
ight be achieved by coexpression of the herpes sim-
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Posttransplantation Adoptive Transfer of T Cells
Blex virus thymidine kinase or, preferably, a minimally
mmunogenic suicide construct derived from human
aspase domains [49-52].
TRATEGIES TO FACILITATE ENGRAFTMENT AND IN
IVO EXPANSION OF ADOPTIVELY TRANSFERRED
CELLS
Clinical efﬁcacy of adoptive therapy with geneti-
ally modiﬁed re-directed T cells will require both
dequate in vivo numeric expansion of transferred T
ells and a sufﬁcient duration of persistence. More-
ver, transferred cells must continue to express TcR
r CAR transgenes and retain re-directed effector
unctioning in the tumor-bearing host. Not only does
xtensive ex vivo propagation of T cells represent
igniﬁcant labor-intensive production demands, but it
lso potentially drives cells closer to replicative senes-
ence or renders them functionally anergic. Under-
tanding the parameters by which a small number of
x vivo–expanded adoptively transferred T cells can
xpand in the recipient and persist for prolonged pe-
iods of time is of considerable importance for devel-
ping adoptive therapy and is being approached both
y studying the inﬂuence of in vitro/in vivo cytokine
upport of these effector cells and by manipulating the
ymphoid homeostatic milieu of the T-cell recipient
efore adoptive transfer.
Iatrogenic lymphopenia triggers the expansion of
esidual T cells and increases the number of thymic
mmigrants to restore the T-cell pool size back to a
omeostatic set point [53]. The mechanism by which
he total body T-cell mass is regulated relies in part on
imiting amounts of T-cell homeostatic cytokines,
uch as IL-15 and IL-7. As lymphocytes numerically
xpand, consumption and, thus, availability of homeo-
tatic cytokines becomes limiting for further net in-
reases in total body lymphocyte numbers. T-cell recon-
titution after lymphodepletion can result in extensive
emodeling of the TcR repertoire as a consequence of
isparate rates of homeostatically driven clonal T-cell
xpansion [54,55]. Skewing the population of recov-
ring T cells to overrepresent a T-cell repertoire of a
esired antigen speciﬁcity by means of vaccination
uring the recovery phase or by transferring antigen-
peciﬁc T cells early in the repopulating phase might
e therapeutically valuable by facilitating the expan-
ion of antitumor T cells. Murine models of lym-
hodepletion followed by adoptive transfer of T cells
rovide proof of concept that this strategy results in a
arked enhancement of the magnitude of persistence
nd therapeutic efﬁcacy of adoptively transferred T
ells [56-58]. Childs et al. used immunodepleting che-
otherapy in humans before the adoptive transfer of
ligoclonal melanoma-speciﬁc TILs accompanied by
igh-dose IL-2 therapy [7]. The ex vivo–expanded T t
B&MTells were infused when circulating lymphocyte counts
ad decreased to 20/L, and this approach led to
arked expansion of transferred T cells and an ex-
ended duration of persistence and correlated with
umor regression. This initial clinical observation re-
uires careful delineation of which variables are nec-
ssary to achieve efﬁcient lymphodepletion-induced
-cell proliferation and how that might be achieved
ith more speciﬁc and less toxic immunodepleting
gents and cytokine support.
A conceptually attractive strategy to enhance the
ersistence of TCR- and CAR-transgene–expressing
ffectors is the approach of expressing tumor-speciﬁc
CR/CARs on T cells with endogenous TCR antigen
peciﬁcity for viruses to which the host has robust
mmunity, thus creating bispeciﬁc T cells. Of partic-
lar interest is the grafting of tumor-speciﬁc antigen
eceptors on to T cells speciﬁc for latent viruses such
s CMV and EBV. Transferred bispeciﬁc T cells with
ombined viral- and tumor-speciﬁc antigen receptors
ave the opportunity to encounter viral antigens in the
ontext of professional antigen-presenting cells that
oexpress immunostimulatory ligands and cytokines
or co-stimulation. Rossig et al. have demonstrated
roof of concept of this approach by using EBV-
peciﬁc T cells modiﬁed to express a GD2-speciﬁc
cFv- construct, thus demonstrating that these T-cell
ines display antigen-speciﬁc effector function for
oth EBV targets, as well as GD2 tumors [59].
sing bispeciﬁc T cells with viral speciﬁcities for
ersistent viruses such as EBV and CMV requires
areful consideration of how these cells can be con-
rolled should viral reactivation and viremia cause an
xuberant expansion of the transferred bispeciﬁc T
ells that results in inﬂammatory changes in tumors
ocated in sensitive anatomic locations, such as the
ung, airways, and brain. Additionally, the duration of
ersistence of these bispeciﬁc T cells might be pro-
onged or indeﬁnite; thus, if the tumor-targeting
AR’s speciﬁcity is directed against a cell lineage–
peciﬁc epitope, for example, CD19, in which case
epopulation of nonneoplastic CD19 B cells is de-
ired after tumor clearance, then controlling the du-
ation of the persistence of these transferred T cells
ill important. In vivo ablation of gene-modiﬁed T
ells through engineered suicide constructs by using
erpes simplex virus thymidine kinase, trimerizable
AS, and dimerizable caspases are suicide strategies
hat can potentially mitigate these issues [52].
Driving the expansion of tumor–re-directed T
ells through vaccination with antigens that trigger
hrough the endogenous TcR may provide for a con-
rollable means of enhancing the number and duration
f persistence of transferred T cells, particularly anti-
umor CAR-expressing T cells. Hwu et al. have de-
cribed the capacity to drive the expansion of adop-
ively transferred CAR-expressing alloreactive T cells
37
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3y the delivery of irradiated allogeneic splenocytes to
nimals [60]. Alloantigen in vivo–reactivated CAR T
ells expanded in numbers and resulted in augmented
AR-mediated tumor recognition and clearance. Our
aboratory’s efforts are directed toward generating
AR-expressing T cells with endogenous TcR speci-
city for inﬂuenza matrix protein 1. Whereas clini-
ally available live attenuated inﬂuenza vaccines might
e used to drive the expansion of transferred bispeciﬁc
cells, we have also devised an approach to vaccinate
atients with irradiated autologous T cells that have
een genetically modiﬁed to express inﬂuenza matrix
rotein 1, on the basis of the observation by Berger et
l. that intravenous delivery of HyTK T cells results
n the generation of robust anti-HyTK T-cell rejec-
ion responses [61]. These genetically modiﬁed anti-
en-presenting T cells express HLA class I and class II
nd T-cell co-stimulatory ligands and can be manu-
actured by using the same procedures as the CAR-
edirected T cells.
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